Navigation Links
eFuture Signs Contract to Provide Tiens Group with Retail Business Management System
Date:7/23/2008

ture will first deploy mySHOP 3.0 in a pilot stage covering Tiens Group's four subsidiary stores, four direct-sales stores and 40 franchised chain stores in China and expects the pilot stage to be operational by December 2008. After the completion of an initial rollout, eFuture and Tiens Group expect to further collaborate to complete a nationwide expansion of the system to a further 96 subsidiary stores, 96 direct-sales stores and 1,000 franchised chain stores in 2009.

In July 2006, Tiens Group selected eFuture's ONE POS-ERP R2003 Super Market Management System for its Bannerstore Supermarket. Since its selection, the R2003 Super Market Management system has been successfully implemented in Bannerstore's headquarters back-office, six subsidiary stores, 17 direct-sales stores and 23 franchised chain stores.

About Tiens Group Co., Ltd.

Founded in 1995 by Mr. Li Jinyuan, Tiens Group Co., Ltd. (Amex: TBV) is a large-scale global enterprise with operations in over 190 countries and regions and with a customer base of over 16 million worldwide. Since 1995, Tiens Group has maintained continual, stable, and rapid growth. With an anchor business in advanced biotechnology, particularly in the areas of health food, health care, beauty care and home care products, Tiens Group is also involved in financing, real estate development, education, cultural exchanges, and modern logistics. Tiens Group is headquartered at the Henderson Center in Beijing, China, and has production plants in the Wuqing New Technology Development Zone of Tianjin, China.

Tiens Group is a direct selling company that is based on advanced biotechnology devoted to developing health and wellness products and a culture for a healthy lifestyle. Tiens Group operates
'/>"/>

SOURCE eFuture Information Technology Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
2. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
3. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
4. Sigma-Aldrich Signs Agreement With Plextronics to Distribute Plexcore(R) Organic Electronics Materials
5. GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
6. Medline Signs 3-Year Purchasing Agreement for Mouth Rinse From Chester Labs
7. Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests
8. Digirad Corporation Signs Letter of Understanding With Johns Hopkins University School of Medicine
9. Cepheid Signs Group Purchasing Contract with Novation, the Nations Largest Healthcare Contracting Organization
10. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
11. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):The Academy of Natural Sciences and Temple Press revive rare natural history work in new book 2Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 2Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 4Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 5Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 6GSK Limits Medical Education Funding to Independent Programs With Highest Impact on Patient Care 57764 1GSK Limits Medical Education Funding to Independent Programs With Highest Impact on Patient Care 57764 2GSK Limits Medical Education Funding to Independent Programs With Highest Impact on Patient Care 57764 3ANAVEX completes scale up manufacturing of ANAVEX 2 73 for Phase I Alzheimers disease clinical trials 5022 1ANAVEX completes scale up manufacturing of ANAVEX 2 73 for Phase I Alzheimers disease clinical trials 5022 2ANAVEX completes scale up manufacturing of ANAVEX 2 73 for Phase I Alzheimers disease clinical trials 5022 3With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 1With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 2With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 3With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 4With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 5With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 6